Member-only information. Become a member to access this information. Procurement notices from over 850+ sources of tenders and grants published by donors, development banks, foundations, and international financial institutions (IFIs) are available here.
A result overview of the evaluation that closed on 18 April 2018 is now available under the "Topic conditions and documents" section.
27 April 2018 09:57
The submission of proposals to the 21 topics of H2020-SC1-2018-Single-Stage-RTD closed on 18 April 2018. A total of 324 proposals were submitted. The number of proposals per topic is as follows:
- SC1-BHC-27-2018 (RIA): 28
01 March 2018 11:36
Notice regarding page limits applicable to proposals: applicants are allowed to remove the page break in the cover page of the template for the technical annex, i.e. the proposal text can start on the cover page.
07 November 2017 00:30
The submission session is now available for: SC1-BHC-27-2018(RIA)
TOPIC : New testing and screening methods to identify endocrine disrupting chemicals
There are a variety of natural and anthropogenic chemicals that can produce adverse effects via a disruption of the body's endocrine (hormone) system, referred to as endocrine disruptors (EDs)[1]. EDs are of increasing importance in chemical regulations in the European Union, and criteria to identify EDs have recently been presented for two pieces of EU legislation (Biocidal Product Regulation and Plant Protection Products Regulation)[2].
In the EU, the legislation regulating chemical substances often includes their screening and testing according to the EU test methods regulation[3], which predominantly contains test methods developed under the OECD[4]. The current testing tools, including regulatory in vivo tests and novel in vitro assays, do not appropriately identify effects related to certain less studied endocrine-mediated pathways or health outcomes, in which EDs may be implicated. Moreover, the new ED criteria require information about both the adverse effects and the endocrine mode of action.
Scope:
New and improved approaches are needed to increase the quality, the efficiency and the effectiveness of existing methods to meet demanding and evolving regulatory requirements worldwide. In consultation with relevant regulatory bodies, research should improve and harmonise screening and testing protocols/strategies and hazard/risk assessments by developing better and faster tools, test methods or models, including in vitro and in vivo tests, high-throughput and in silico methods (e.g. QSAR), potentially combined with research on adverse outcomes pathways. For in vitro tests, appropriate coupling of their results to human health effects should be ensured. Information is also needed as regards how epidemiological and field monitoring data, which are also to be considered as data sources in a regulatory context, can be used to gain information about possible associations between levels of exposure to specific chemicals and ED-related effects. Focus should be on the most urgent regulatory needs, e.g., methods addressing the thyroid axis, developmental neurotoxicity, metabolic disorders, female reproduction and non-genotoxic carcinogenicity. Proposals should involve, in addition to academic researchers, regulatory agencies and other actors as appropriate. Proposers should consider sex and gender analysis when relevant. International cooperation is essential. Proposals are required to describe how they will contribute to ongoing international ED related activities (e.g. OECD work, EU level databases), including decision schemes under development. To speed up regulatory uptake of tests, validation is an essential step to be included in the proposals.
The Commission considers that a proposal requesting an EU contribution between EUR 4 to 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.
Collaboration between successful proposals will be encouraged.
Proposals could consider the involvement of the European Commission Joint Research Centre (JRC) as an added value in order to provide an effective interface between the research activities and regulatory aspects and/or to translate the research results into validated test methods and strategies fit for regulatory purpose. In that respect, the JRC will collaborate with any successful proposal.
Expected Impact:
Improved hazard and risk assessment of EDs, including in the workplace.
Novel ED assay candidates for regulatory use.
Support for the OECD work on testing and assessing chemicals for ED identification.
Enhanced international cooperation.
Contribution to the development of an international strategy and guidelines for testing EDs and assessing associated hazard and risk.
[2]Communication from the Commission to the European Parliament and the Council on endocrine disruptors and the draft Commission acts setting out scientific criteria for their determination in the context of the EU legislation on plant protection products and biocidal products: http://ec.europa.eu/health/endocrine_disruptors/policy/index_en.htm
Horizon 2020 - is a Framework Programme for Research and Technological Development, and is created by the European Union in order to support and encourage research in the European Research Area (ERA). This is the biggest EU Research and Innovation programme ever with nearly €80 billion of funding available over 7 years (2014 to 2020). By coupling research and innovation, Horizon 2020 is helping to achieve this with its emphasis on excellent science, industrial leadership and tackling societal challenges. The goal is to ensure Europe produces world-class science, removes barriers to innovation and makes it easier for the public and private sectors to work together in delivering innovation. The Horizon 2020 programme running from 2014 to 2020 has a €79 billion budget (a 46% increase over FP7).
It is structured around three core pillars:
Excellent Science (~€24.4bn)
Industrial Leadership (~€17bn)
Societal Challenges (~€29.7bn)
Type of projects: mostly grants, no supplies, no works.
In order to see Horizon 2020 opportunities on DevelopmentAid, please click here.
Switzerland maintains advanced rail networks, road systems, energy infrastructure, and digital connectivity to support its high-value industrial and financial economy. Significant investment focuses on rail tunnels, sustainable transport, and renewable energy integration. Infrastructure financing is supported by strong public finances and long-term strategic planning. Climate neutrality goals, alpine geography, and cross-border integration influence infrastructure development.
Nr. of tenders: 12777 Nr. of grants: 4288 Nr. of donors: 428 Nr. of jobs: 112
Haven't found what you're looking for? Get in touch with us using our contact page.
Where can I find international grant opportunities?
DevelopmentAid collects grant opportunities from bilateral donors, multilateral agencies, foundations, and international organizations in one centralized platform.
Who can apply for grants listed on DevelopmentAid?
Grants are typically open to NGOs, civil society organizations, research institutions, public entities, and sometimes private organizations or consortia.
Does DevelopmentAid help with grant applications?
DevelopmentAid does not write or submit applications, but it provides access to full call details, guidelines, deadlines, and donor information needed to apply.